Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

Wall Street’s average price target for Nuvation Bio (NUVB) implies 91.9% upside, supported by a positive trend in earnings estimate revisions. However, the reliability of price targets is noted as questionable, suggesting the setup is constructive but not definitive. The most immediate implication is improved sentiment around forward earnings rather than a confirmed operational catalyst.